EUVIMEDEUVIMED entdecken
Open Access

Dual-action small-molecule VSP-51-2 ameliorates polycystic ovary syndrome via PPARγ modulation and AKR1C3 inhibition

Xiawen Liu iD, Xiufen Zheng iD, Lei Ma iD, Ziqing Yao, Xuehua Zheng, Miao Liang iD, Xinhong Wu, Silin Zhang, Xianglin Zhou, Leying Zhu, Zhi Zhou iD, H Eric Xu iD und 1 weitere

Science Advances · 13.11.2026 · 12 (46)

DOI: 10.1126/sciadv.aee9754 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 13.11.2026. Verfasst von Xiawen Liu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of Molecular Target and Clinical Pharmacology, the State Key Laboratory of Respiratory Disease, The Third Affilia…. Hauptthemen laut MEDLINE: Polycystic Ovary Syndrome, Aldo-Keto Reductase Family 1 Member C3, PPAR gamma, Small Molecule Libraries. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Guandong Natural Science Foundation, Ministry of Science and Technology of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Polycystic ovary syndrome (PCOS), a prevalent multifactorial endocrine disorder, is inadequately managed by current therapies that fail to concurrently target its core metabolic (insulin resistance) and reproductive (hyperandrogenism) pathologies. We report VSP-51-2, a dual-target lead compound initially engineered as a selective PPARγ modulator that unexpectedly exerts potent uncompetitive inhibition of the androgen-synthesizing enzyme AKR1C3 through a putative allosteric mechanism. In preclinical PCOS models, VSP-51-2 restored regular estrous cyclicity, improved ovarian follicular morphology, enhanced systemic insulin sensitivity, suppressed hyperandrogenism, and did not significantly perturb measured hypothalamic-pituitary-ovarian (HPO) axis hormonal parameters. Mechanistically, it blocks PPARγ phosphorylation at Ser 273 , thereby enhancing adiponectin secretion and GLUT4-mediated glucose uptake, and is predicted to bind a putative allosteric pocket of AKR1C3 to constrain androgen biosynthesis. These findings support VSP-51-2 as a preclinical proof-of-concept compound for a dual-target strategy that addresses metabolic dysfunction and androgen excess through a unified molecular scaffold.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polycystic Ovary SyndromeAldo-Keto Reductase Family 1 Member C3PPAR gammaSmall Molecule LibrariesFemaleAnimalsHumansInsulin Resistance

Substanzen

Aldo-Keto Reductase Family 1 Member C3PPAR gammaAKR1C3 protein, humanSmall Molecule Libraries

Autor:innen und Institutionen

  • Guangdong Provincial Key Laboratory of Molecular Target and Clinical Pharmacology, the State Key Laboratory of Respiratory Disease, The Third Affiliated Hospital & School of Pharmaceutical Sciences, Guangzhou Medical Un…
  • CAS Key Laboratory of Receptor Research, Center for Structure and Function of Drug Targets, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.

ORCID-Profile: Xiawen Liu, Xiufen Zheng, Lei Ma, Miao Liang, Zhi Zhou, H Eric Xu, Wei Yi

Förderung

  • National Natural Science Foundation of China
  • Guandong Natural Science Foundation
  • Ministry of Science and Technology of China
  • Shanghai Municipal Science and Technology Major Project
  • CAS Strategic Priority Research Program
  • Guangdong Natural Science Funds for Distinguished Young Scholar

Zitieren

APA

Liu, X., Zheng, X., Ma, L., Yao, Z., Zheng, X., Liang, M., Wu, X., Zhang, S., Zhou, X., Zhu, L., Zhou, Z., Xu, H. E., & Yi, W. (2026). Dual-action small-molecule VSP-51-2 ameliorates polycystic ovary syndrome via PPARγ modulation and AKR1C3 inhibition. Science Advances, 12(46). https://doi.org/10.1126/sciadv.aee9754

Vancouver

Liu X, Zheng X, Ma L, Yao Z, Zheng X, Liang M, et al. Dual-action small-molecule VSP-51-2 ameliorates polycystic ovary syndrome via PPARγ modulation and AKR1C3 inhibition. Science Advances. 2026;12(46). doi:10.1126/sciadv.aee9754

BibTeX
@article{Liu2026,
  author = {Liu, Xiawen and Zheng, Xiufen and Ma, Lei and Yao, Ziqing and Zheng, Xuehua and Liang, Miao and Wu, Xinhong and Zhang, Silin and Zhou, Xianglin and Zhu, Leying and Zhou, Zhi and Xu, H Eric and Yi, Wei},
  title = {Dual-action small-molecule VSP-51-2 ameliorates polycystic ovary syndrome via PPARγ modulation and AKR1C3 inhibition},
  journal = {Science Advances},
  year = {2026},
  volume = {12},
  number = {46},
  doi = {10.1126/sciadv.aee9754}
}
Kostenlos starten →